Skip to main content

Advertisement

SpringerLink
Log in

Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objectives

Hip arthritis plays a critical role in the prognosis of ankylosing spondylitis (AS). Dose reduction of tumor necrosis factor inhibitors preserves general improvement of AS, so this study attempted to examine the equivalence between Yisaipu® tapering and conventional therapy for hip arthritis in AS patients, using clinical parameters and magnetic resonance image (MRI).

Methods

AS patients received this etanercept-biosimilar injections (50 mg/week) in the first 12 weeks. Participants in the tapering group were treated with this reagent 50 mg every other week from week 13 to week 24, while the control group kept undergoing full-dose therapy. Clinical and laboratory parameters were assessed at baseline, week 12 and week 24. MRI examination of hip was performed at baseline and week 24.

Results

One hundred and thirty-six patients were enrolled, and 80 of them were in the tapering group. Linear mixed model revealed that main effects of tapering group with control group as reference in disease activity parameters were insignificant (p > 0.05). Main effects of baseline with week 24 as reference were significant (p < 0.05), but main effects of week 12 with week 24 as reference were not (p > 0.05). Prevalence of acute inflammatory change in MRI significantly decreased in the tapering group (76.88% vs 20.00%, p < 0.05) and control group (76.79% vs 19.64%, p < 0.05). Influence of both treatments on acute inflammatory change was equivalent (p > 0.05).

Conclusion

Efficacy of Yisaipu® tapering treatment is comparable to the full-dose therapy for hip arthritis in AS patients. Both treatments maintain remission of hip arthritis after patients achieved low disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jeong H, Eun YH, Kim IY, Kim H, Lee J, Koh EM, Cha HS (2017) Characteristics of hip involvement in patients with ankylosing spondylitis in Korea. Korean J Intern Med 32(1):158–164. https://doi.org/10.3904/kjim.2015.229

    Article  PubMed  Google Scholar 

  2. Huang ZG, Zhang XZ, Hong W, Wang GC, Zhou HQ, Lu X, Wang W (2013) The application of MR imaging in the detection of hip involvement in patients with ankylosing spondylitis. Eur J Radiol 82(9):1487–1493. https://doi.org/10.1016/j.ejrad.2013.03.020

    Article  PubMed  Google Scholar 

  3. Zou YC, Yang XW, Yuan SG, Zhang P, Li YK (2016) Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro. Drug Des Devel Ther 10:933–948. https://doi.org/10.2147/DDDT.S97463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sakellariou G, Iagnocco A, Meenagh G, Riente L, Filippucci E, Delle Sedie A, Scirè CA, Bombardieri S, Grassi W, Valesini G, Montecucco C (2012) Ultrasound imaging for the rheumatologist XXXVII. Sonographic assessment of the hip in ankylosing spondylitis patients. Clin Exp Rheumatol 30(1):1–5

    CAS  PubMed  Google Scholar 

  5. Ungprasert P, Erwin PJ, Koster MJ (2017) Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Clin Rheumatol 36(7):1569–1577. https://doi.org/10.1007/s10067-017-3693-7

    Article  PubMed  Google Scholar 

  6. Nystad TW, Furnes O, Havelin LI, Skredderstuen AK, Lie SA, Fevang BT (2014) Hip replacement surgery in patients with ankylosing spondylitis. Ann Rheum Dis 73(6):1194–1197. https://doi.org/10.1136/annrheumdis-2013-203963

    Article  PubMed  Google Scholar 

  7. Chen MH, Lee MH, Liao HT, Chen WS, Lai CC, Tsai CY (2018) Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. Clin Rheumatol 37(2):429–438. https://doi.org/10.1007/s10067-017-3965-2

    Article  PubMed  Google Scholar 

  8. Li J, Wang X, Han Z, Zhang Y, Wang Y, Zhang Y, Li W (2016) Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population. Int J Immunopathol Pharmacol 29(3):510–515. https://doi.org/10.1177/0394632016656013

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lian F, Yang X, Liang L, Xu H, Zhan Z, Qiu Q, Ye Y (2012) Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population. Rheumatol Int 32(6):1663–1667. https://doi.org/10.1007/s00296-011-1844-8

    Article  CAS  PubMed  Google Scholar 

  10. Wu B, Song Y, Leng L, Bucala R, Lu LJ (2015) Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol 33(1):20–26

    PubMed  Google Scholar 

  11. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368

    Article  Google Scholar 

  12. Machado PM, Landewé R, Heijde DV, Assessment of SpondyloArthritis international Society (ASAS) (2018) Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis 77(10):1539–1540. https://doi.org/10.1136/annrheumdis-2018-213184

    Article  PubMed  Google Scholar 

  13. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 21(12):2286–2291

    CAS  PubMed  Google Scholar 

  14. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 21(12):2281–2285

    CAS  PubMed  Google Scholar 

  15. Turan Y, Bayraktar K, Kahvecioglu F, Tastaban E, Aydin E, Kurt Omurlu I, Berkit IK (2014) Is magnetotherapy applied to bilateral hips effective in ankylosing spondylitis patients? A randomized, double-blind, controlled study. Rheumatol Int 34(3):357–365. https://doi.org/10.1007/s00296-013-2941-7

    Article  PubMed  Google Scholar 

  16. Tiwari A, Karkhur Y, Maini L (2018) Total hip replacement in tuberculosis of hip: a systematic review. J Clin Orthop Trauma 9(1):54–57. https://doi.org/10.1016/j.jcot.2017.09.013

    Article  PubMed  Google Scholar 

  17. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3–17. https://doi.org/10.1136/annrheumdis-2017-211734

    Article  PubMed  Google Scholar 

  18. McGowan B, Bennett K, Silke C, Whelan B (2016) Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol 35(3):715–721. https://doi.org/10.1007/s10067-014-2823-8

    Article  PubMed  Google Scholar 

  19. MacKay K, Brophy S, Mack C, Doran M, Calin A (2000) The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol 27(12):2866–2872

    CAS  PubMed  Google Scholar 

  20. Baraliakos X, Braun J (2010) Hip involvement in ankylosing spondylitis: what is the verdict? Rheumatology (Oxford) 49(1):3–4. https://doi.org/10.1093/rheumatology/kep298

    Article  Google Scholar 

  21. Wang D, Ma L, Wu D (2011) Efficacy of etanercept in ankylosing spondylitis hip lesions. Joint Bone Spine 78(5):531–532. https://doi.org/10.1016/j.jbspin.2011.03.023

    Article  PubMed  Google Scholar 

  22. Arends S, van der Veer E, Kamps FB, Houtman PM, Bos R, Bootsma H, Brouwer E, Spoorenberg A (2015) Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol 33(2):174–180

    PubMed  Google Scholar 

  23. Mörck B, Pullerits R, Geijer M, Bremell T, Forsblad-d'Elia H (2013) Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediat Inflamm 2013:289845. https://doi.org/10.1155/2013/289845

    Article  CAS  Google Scholar 

  24. Chingcuanco F, Segal JB, Kim SC, Alexander GC (2016) Bioequivalence of biosimilar tumor necrosis factor-α inhibitors compared with their reference biologics: a systematic review. Ann Intern Med 165(8):565–574. https://doi.org/10.7326/M16-0428

    Article  PubMed  Google Scholar 

  25. Liu S, Rovine MJ, Molenaar PC (2012) Selecting a linear mixed model for longitudinal data: repeated measures analysis of variance, covariance pattern model, and growth curve approaches. Psychol Methods 17(1):15–30. https://doi.org/10.1037/a0026971

    Article  PubMed  Google Scholar 

  26. Lin Z, Gu J, He P, Gao J, Zuo X, Ye Z, Shao F, Zhan F, Lin J, Li L, Wei Y, Xu M, Liao Z, Lin Q (2011) Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients. Rheumatol Int 31(2):233–238. https://doi.org/10.1007/s00296-009-1313-9

    Article  PubMed  Google Scholar 

  27. Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J (2011) The ankylosing spondylitis disease activity score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford) 50(8):1466–1472. https://doi.org/10.1093/rheumatology/ker087

    Article  CAS  Google Scholar 

  28. Zheng W, Li J, Zhao J, Liu D, Xu W (2014) Development of a valid simplified Chinese version of the Oxford hip score in patients with hip osteoarthritis. Clin Orthop Relat Res 472(5):1545–1551. https://doi.org/10.1007/s11999-013-3403-y

    Article  PubMed  Google Scholar 

  29. Vander Cruyssen B, Vastesaeger N, Collantes-Estévez E (2013) Hip disease in ankylosing spondylitis. Curr Opin Rheumatol 25(4):448–454. https://doi.org/10.1097/BOR.0b013e3283620e04

    Article  CAS  PubMed  Google Scholar 

  30. Song R, Chung SW, Lee SH (2017) Radiographic evidence of hip joint recovery in patients with ankylosing spondylitis after treatment with anti-tumor necrosis factor agents: a case series. J Rheumatol 44(11):1759–1760. https://doi.org/10.3899/jrheum.161401

    Article  PubMed  Google Scholar 

  31. Konsta M, Sfikakis PP, Bournia VK, Karras D, Iliopoulos A (2013) Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis. Clin Rheumatol 32(8):1229–1232. https://doi.org/10.1007/s10067-013-2263-x

    Article  CAS  PubMed  Google Scholar 

  32. Verbruggen G (2006) Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 45(2):129–138

    Article  CAS  Google Scholar 

  33. Aguila Maldonado R, Ruta S, Valuntas ML, García M (2017) Ultrasonography assessment of heel entheses in patients with spondyloarthritis: a comparative study with magnetic resonance imaging and conventional radiography. Clin Rheumatol 36(8):1811–1817. https://doi.org/10.1007/s10067-017-3723-5

    Article  PubMed  Google Scholar 

  34. Sudoł-Szopińska I, Znajdek M, Gietka P, Vasilevska-Nikodinovska V, Patrovic L, Salapura V (2017) Imaging of juvenile spondyloarthritis. Part II: ultrasonography and magnetic resonance imaging. J Ultrason 17(70):176–181. https://doi.org/10.15557/JoU.2017.0026

    Article  PubMed  PubMed Central  Google Scholar 

  35. Chen D, Yuan S, Zhan Z, Xiao Y, Li H, Liang L, Yang X (2016) Early-stage hip involvement in patients with ankylosing spondylitis: a Chinese study based on magnetic resonance imaging. Mod Rheumatol 26(6):933–939. https://doi.org/10.3109/14397595.2016.1153232

    Article  PubMed  Google Scholar 

  36. Hermann KG, Bollow M (2014) Magnetic resonance imaging of sacroiliitis in patients with spondyloarthritis: correlation with anatomy and histology. Rofo 186(3):230–237. https://doi.org/10.1055/s-0033-1350411

    Article  PubMed  Google Scholar 

  37. Althoff CE, Sieper J, Song IH, Weiß A, Diekhoff T, Haibel H, Hamm B, Hermann KG (2016) Comparison of clinical examination versus whole-body magnetic resonance imaging of enthesitis in patients with early axial spondyloarthritis during 3 years of continuous etanercept treatment. J Rheumatol 43(3):618–624. https://doi.org/10.3899/jrheum.150659

    Article  PubMed  Google Scholar 

  38. Cantarini L, Fabbroni M, Talarico R, Costa L, Caso F, Cuneo GL, Frediani B, Faralli G, Vitale A, Brizi MG, Sabadini L, Galeazzi M (2015) Effectiveness of adalimumab in non-radiographic axial spondyloarthritis: evaluation of clinical and magnetic resonance imaging outcomes in a monocentric cohort. Medicine (Baltimore) 94(30):e1170. https://doi.org/10.1097/MD.0000000000001170

    Article  CAS  Google Scholar 

  39. Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225. https://doi.org/10.1002/art.30393

    Article  PubMed  Google Scholar 

  40. Lee H, Jung Y, Song S, Lee J, Shim H, Kang W, Kim E (2017) Dosage and duration of etanercept therapy for ankylosing spondylitis: a meta-analysis. Int J Technol Assess Health Care 33:69–75. https://doi.org/10.1017/S0266462317000150

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Prof. Jun Yang from the Jinan University, for his statistical advice.

Funding

This work was supported by the Natural Science Foundation of Guangdong Province (No. 2017A030313526), Research Foundation for the Introduction of Talent, Guangdong Second Provincial General Hospital (No. 2014001), and Medical Scientific Research Foundation of Guangdong Province (No. A2015517).

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, No. 466 Xingangzhong Road, Guangzhou, 510317, China

    Zhi-Xiang Huang, Wei-Ming Deng, Xin Guo, Zheng-Ping Huang, Yu-Kai Huang & Tian-Wang Li

  2. Department of Medical Imaging, Guangdong Second Provincial General Hospital, Guangzhou, China

    Chu-Lan Lin

Authors
  1. Zhi-Xiang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei-Ming Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zheng-Ping Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-Kai Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chu-Lan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tian-Wang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tian-Wang Li.

Ethics declarations

This study was approved by the ethics committee of Guangdong second provincial general hospital (2015-KLYY-0015). Written informed consents in accordance with the declaration of Helsinki were given by participants.

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, ZX., Deng, WM., Guo, X. et al. Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study. Clin Rheumatol 38, 1595–1604 (2019). https://doi.org/10.1007/s10067-019-04466-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-019-04466-9

Keywords

Search

Navigation